AI Article Synopsis
- Researchers developed a new treatment for blastic plasmacytoid dendritic cell neoplasm (BPDCN) using an engineered form of diphtheria toxin.
- The diphtheria toxin is modified to specifically target cancerous cells by fusing it with interleukin (IL)3.
- This innovative approach aims to improve the effectiveness of treatment for BPDCN by directly targeting the malignant cells.
Article Abstract
In this issue of Blood, Frankel et al describe a novel treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) using an engineered version of diphtheria toxin that is targeted to malignant cells via a fusion with interleukin (IL)3 (see panel A).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4102704 | PMC |
| http://dx.doi.org/10.1182/blood-2014-06-578633 | DOI Listing |
Publication Analysis
Top Keywords
diphtheria toxin
8
targeted diphtheria
4
toxin treat
4
treat bpdcn
4
bpdcn issue
4
issue blood
4
blood frankel
4
frankel describe
4
describe novel
4
novel treatment
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!